Stay updated on Nivolumab vs Cabiralizumab in T Cell Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Cabiralizumab in T Cell Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Cabiralizumab in T Cell Lymphoma Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:18:17.000Z thumbnail image
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    8 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a modification in the enrollment number for the multicenter trial evaluating the combination of nivolumab and cabiralizumab in patients with relapsed/refractory peripheral T cell lymphoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:16.000Z thumbnail image
  7. Check
    22 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria for clinical trials, including examples such as general health condition or prior treatments, and a link to general information about clinical research.
    Difference
    51%
    Check dated 2024-05-22T19:49:47.000Z thumbnail image
  8. Check
    44 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:39:52.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Cabiralizumab in T Cell Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Cabiralizumab in T Cell Lymphoma Clinical Trial page.